# Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

> **NCT03190174** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sarcoma Oncology Research Center, LLC** · enrollment: 34 (actual)

## Conditions studied

- Ewing Sarcoma
- PEComa
- Epithelioid Sarcoma
- Desmoid Tumor
- Chordoma
- Non Small Cell Lung Cancer
- Urothelial Carcinoma
- Melanoma
- Renal Cell Carcinoma
- Squamous Cell Carcinoma
- Hepatocellular Carcinoma
- Classical Hodgkin Lymphoma
- Colorectal Cancer
- MTOR Activating Mutation

## Interventions

- **DRUG:** Nab-Rapamycin
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03190174
- **Lead sponsor:** Sarcoma Oncology Research Center, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-24
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-02
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03190174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03190174, "Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03190174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*